A democratized platform for mapping the spatial epigenome in tissue

用于绘制组织空间表观基因组图谱的民主化平台

• 批准号: 10822023
• 负责人: Jeffrey Sabina
• 金额: $ 139.08万
• 依托单位: ATLASXOMICS INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-19 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10822023
• 关键词: ATAC-seq; Address; Adoption; Anatomy; Area; Bar Codes; Binding; Bioinformatics; Biological; Biological Assay; Biology; Biomedical Research; Biotechnology; Brain; Cancer Biology; Capital; Cardiac; Cardiovascular Diseases; Cause of Death; Cell Communication; Cells; Chromatin; Closure by clamp; Collaborations; Complex; Computer software; Custom; Cutaneous Lymphoma; DNA; DNA sequencing; Data; Data Analyses; Data Set; Democracy; Development; Dimensions; Disease; Disease Progression; Elements; Embryo; Epigenetic Process; Equipment; Feedback; Gene Expression; Genetic; Genetic Transcription; Genome; Germinoma; Goals; Grant; Healthcare; Human; Immune; Industry Standard; Location; Malignant Neoplasms; Manuals; Manuscripts; Maps; Marketing; Methods; Microfluidic Microchips; Microfluidics; Mus; Pathology; Performance; Phase; Phenotype; Play; Population; Positioning Attribute; Price; Proteomics; Protocols documentation; Publications; RNA; Reproducibility; Research; Research Personnel; Resistance; Resolution; Role; Running; Sampling; Scientist; Site; Small Business Innovation Research Grant; Spottings; Standardization; Structure; Technology; Time; Tissues; Training; Transposase; Universities; Untranslated RNA; XCL1 gene; bioinformatics tool; brain tissue; cancer therapy; cardiovascular disorder therapy; care burden; commercial application; commercialization; computational pipelines; computerized data processing; cost; data analysis pipeline; data exploration; data integration; data reduction; design; effective therapy; epigenome; epigenomics; genome-wide; immune cell infiltrate; improved; innovation; insight; interest; melanoma; next generation; next generation sequencing; novel; novel strategies; patient response; prognostic tool; therapeutic effectiveness; therapy resistant; tool; transcription factor; transcriptome sequencing; transcriptomics; treatment response; tumor; tumor microenvironment; user-friendly

PROJECT SUMMARY AtlasXomics Inc. is commercializing the next generation of spatial biology tools to help researchers understand the epigenetic mechanisms of disease. The goal of this SBIR grant is to commercialize a product suite of hardware, consumables, and software to spatially interrogate tissue and generate a new layer of data for better understanding gene expression modulation in tissue. The development of novel research tools is critical to address the significant healthcare burden posed by cancer and cardiovascular disease. Epigenetic dysregulation plays a significant role in disease development and response to therapy, but current technologies are inadequate for capturing epigenetic changes in interacting cell populations. AtlasXomics developed and established proof-of-concept performance of the spatial ATAC-seq (Assay for Transposase Accessible Chromatin) assay. In the Phase I, AtlasXomics successfully transferred the academic protocol into a commercial workflow and met industry standards for ATAC-seq quality in mouse and human cancer tissues. The Company introduced the first commercial epigenomics assay to the market in June 2022. In this proposed Phase II, the Company will increase the price performance of the assay to address feedback from customers and prospects: cover a larger area of tissue, increase cellular resolution, and establish a user-friendly, interactive data analysis suite that enables researchers to seamlessly analyze data. The product of this SBIR will be an all-in-one kit that integrates a suite of hardware, consumables, and bioinformatics tools to enable scientists to explore the epigenetic dimension of disease pathology., e.g., characterize tumor and immune cells spatially in the tissue microenvironment. The product will democratize broad adoption of the spatial epigenomics platform because it does not require costly custom equipment and the proposed bioinformatics workflow will also simplify the analysis of the large epigenomics datasets generated by the assay. This product will help scientists to gain biological insight into the spatial epigenetic mechanisms that drive disease progression and therapy response.

项目概要 AtlasXomics Inc. 正在将下一代空间生物学工具商业化，以帮助 研究人员了解疾病的表观遗传机制。 SBIR 赠款的目标是 将硬件、耗材和软件产品套件商业化，以进行空间询问 组织并生成新的数据层，以更好地理解基因表达调节 组织。新型研究工具的开发对于解决重大医疗保健问题至关重要 癌症和心血管疾病造成的负担。表观遗传失调起着重要作用 在疾病发展和治疗反应中发挥作用，但目前的技术还不够 用于捕获相互作用的细胞群中的表观遗传变化。 AtlasXomics 开发并 建立了空间 ATAC-seq（转座酶测定）的概念验证性能 可及染色质）测定。一期AtlasXomics成功转移学术成果 协议进入商业工作流程并满足小鼠 ATAC-seq 质量的行业标准 和人类癌症组织。该公司推出了第一个商业表观基因组学检测 2022年6月上市。 在拟议的第二阶段中，公司将提高检测的性价比 解决客户和潜在客户的反馈：覆盖更大面积的组织，增加细胞 分辨率，并建立一个用户友好的交互式数据分析套件，使研究人员能够 无缝分析数据。该 SBIR 的产品将是一款集成了 一套硬件、耗材和生物信息学工具，使科学家能够探索 疾病病理学的表观遗传维度，例如，在空间上表征肿瘤和免疫细胞 在组织微环境中。该产品将使空间技术的广泛采用民主化 表观基因组学平台，因为它不需要昂贵的定制设备和建议的 生物信息学工作流程还将简化对生成的大型表观基因组数据集的分析 通过测定。该产品将帮助科学家获得空间表观遗传的生物学见解 驱动疾病进展和治疗反应的机制。